Implementation of Glucose-6-Phosphate Dehydrogenase (G6PD) testing for Plasmodium vivax case management, a mixed method study from Cambodia

Plasmodium vivax remains a challenge for malaria elimination since it forms dormant liver stages (hypnozoites) that can reactivate after initial infection. 8-aminoquinolone drugs kill hypnozoites but can cause severe hemolysis in individuals with Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency....

Full description

Bibliographic Details
Main Authors: Cassidy-Seyoum, SA, Chheng, K, Chanpheakdey, P, Meershoek, A, Hsiang, MS, von Seidlein, L, Tripura, R, Adhikari, B, Ley, B, Price, RN, Lek, D, Engel, N, Thriemer, K
Format: Journal article
Language:English
Published: Public Library of Science 2024
_version_ 1811140237344112640
author Cassidy-Seyoum, SA
Chheng, K
Chanpheakdey, P
Meershoek, A
Hsiang, MS
von Seidlein, L
Tripura, R
Adhikari, B
Ley, B
Price, RN
Lek, D
Engel, N
Thriemer, K
author_facet Cassidy-Seyoum, SA
Chheng, K
Chanpheakdey, P
Meershoek, A
Hsiang, MS
von Seidlein, L
Tripura, R
Adhikari, B
Ley, B
Price, RN
Lek, D
Engel, N
Thriemer, K
author_sort Cassidy-Seyoum, SA
collection OXFORD
description Plasmodium vivax remains a challenge for malaria elimination since it forms dormant liver stages (hypnozoites) that can reactivate after initial infection. 8-aminoquinolone drugs kill hypnozoites but can cause severe hemolysis in individuals with Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency. The STANDARD G6PD test (Biosensor) is a novel point-of-care diagnostic capable of identifying G6PD deficiency prior to treatment. In 2021, Cambodia implemented the Biosensor to facilitate radical cure treatment for vivax malaria. To assess the Biosensor’s implementation after its national rollout, a mixed-methods study was conducted in eight districts across three provinces in Cambodia. Interviews, focus group discussions, and observations explored stakeholders’ experiences with G6PD testing and factors influencing its implementation. Quantitative data illustrative of test implementation were gathered from routine surveillance forms and key proportions derived. Qualitative data were analyzed thematically. The main challenge to implementing G6PD testing was that only 49.2% (437/888) of eligible patients reached health centers for G6PD testing following malaria diagnosis by community health workers. Factors influencing this included road conditions and long distances to the health center, compounded by the cost of seeking further care and patients’ perceptions of vivax malaria and its treatment. 93.9% (790/841) of eligible vivax malaria patients who successfully completed referral (429/434) and directly presented to the health center (360/407) were G6PD tested. Key enabling factors included the test’s acceptability among health workers and their understanding of the rationale for testing. Only 36.5% (443/1213) of eligible vivax episodes appropriately received primaquine. 70.5% (165/234) of female patients and all children under 20 kilograms never received primaquine. Our findings suggest that access to radical cure requires robust infrastructure and income security, which would likely improve referral rates to health centers enabling access. Bringing treatment closer to patients, through community health workers and nuanced community engagement, would improve access to curative treatment of vivax malaria.
first_indexed 2024-09-25T04:18:47Z
format Journal article
id oxford-uuid:5beb0ee5-4dfb-45ef-a835-5e6128683c89
institution University of Oxford
language English
last_indexed 2024-09-25T04:18:47Z
publishDate 2024
publisher Public Library of Science
record_format dspace
spelling oxford-uuid:5beb0ee5-4dfb-45ef-a835-5e6128683c892024-07-28T19:33:46ZImplementation of Glucose-6-Phosphate Dehydrogenase (G6PD) testing for Plasmodium vivax case management, a mixed method study from CambodiaJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:5beb0ee5-4dfb-45ef-a835-5e6128683c89EnglishJisc Publications RouterPublic Library of Science2024Cassidy-Seyoum, SAChheng, KChanpheakdey, PMeershoek, AHsiang, MSvon Seidlein, LTripura, RAdhikari, BLey, BPrice, RNLek, DEngel, NThriemer, KPlasmodium vivax remains a challenge for malaria elimination since it forms dormant liver stages (hypnozoites) that can reactivate after initial infection. 8-aminoquinolone drugs kill hypnozoites but can cause severe hemolysis in individuals with Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency. The STANDARD G6PD test (Biosensor) is a novel point-of-care diagnostic capable of identifying G6PD deficiency prior to treatment. In 2021, Cambodia implemented the Biosensor to facilitate radical cure treatment for vivax malaria. To assess the Biosensor’s implementation after its national rollout, a mixed-methods study was conducted in eight districts across three provinces in Cambodia. Interviews, focus group discussions, and observations explored stakeholders’ experiences with G6PD testing and factors influencing its implementation. Quantitative data illustrative of test implementation were gathered from routine surveillance forms and key proportions derived. Qualitative data were analyzed thematically. The main challenge to implementing G6PD testing was that only 49.2% (437/888) of eligible patients reached health centers for G6PD testing following malaria diagnosis by community health workers. Factors influencing this included road conditions and long distances to the health center, compounded by the cost of seeking further care and patients’ perceptions of vivax malaria and its treatment. 93.9% (790/841) of eligible vivax malaria patients who successfully completed referral (429/434) and directly presented to the health center (360/407) were G6PD tested. Key enabling factors included the test’s acceptability among health workers and their understanding of the rationale for testing. Only 36.5% (443/1213) of eligible vivax episodes appropriately received primaquine. 70.5% (165/234) of female patients and all children under 20 kilograms never received primaquine. Our findings suggest that access to radical cure requires robust infrastructure and income security, which would likely improve referral rates to health centers enabling access. Bringing treatment closer to patients, through community health workers and nuanced community engagement, would improve access to curative treatment of vivax malaria.
spellingShingle Cassidy-Seyoum, SA
Chheng, K
Chanpheakdey, P
Meershoek, A
Hsiang, MS
von Seidlein, L
Tripura, R
Adhikari, B
Ley, B
Price, RN
Lek, D
Engel, N
Thriemer, K
Implementation of Glucose-6-Phosphate Dehydrogenase (G6PD) testing for Plasmodium vivax case management, a mixed method study from Cambodia
title Implementation of Glucose-6-Phosphate Dehydrogenase (G6PD) testing for Plasmodium vivax case management, a mixed method study from Cambodia
title_full Implementation of Glucose-6-Phosphate Dehydrogenase (G6PD) testing for Plasmodium vivax case management, a mixed method study from Cambodia
title_fullStr Implementation of Glucose-6-Phosphate Dehydrogenase (G6PD) testing for Plasmodium vivax case management, a mixed method study from Cambodia
title_full_unstemmed Implementation of Glucose-6-Phosphate Dehydrogenase (G6PD) testing for Plasmodium vivax case management, a mixed method study from Cambodia
title_short Implementation of Glucose-6-Phosphate Dehydrogenase (G6PD) testing for Plasmodium vivax case management, a mixed method study from Cambodia
title_sort implementation of glucose 6 phosphate dehydrogenase g6pd testing for plasmodium vivax case management a mixed method study from cambodia
work_keys_str_mv AT cassidyseyoumsa implementationofglucose6phosphatedehydrogenaseg6pdtestingforplasmodiumvivaxcasemanagementamixedmethodstudyfromcambodia
AT chhengk implementationofglucose6phosphatedehydrogenaseg6pdtestingforplasmodiumvivaxcasemanagementamixedmethodstudyfromcambodia
AT chanpheakdeyp implementationofglucose6phosphatedehydrogenaseg6pdtestingforplasmodiumvivaxcasemanagementamixedmethodstudyfromcambodia
AT meershoeka implementationofglucose6phosphatedehydrogenaseg6pdtestingforplasmodiumvivaxcasemanagementamixedmethodstudyfromcambodia
AT hsiangms implementationofglucose6phosphatedehydrogenaseg6pdtestingforplasmodiumvivaxcasemanagementamixedmethodstudyfromcambodia
AT vonseidleinl implementationofglucose6phosphatedehydrogenaseg6pdtestingforplasmodiumvivaxcasemanagementamixedmethodstudyfromcambodia
AT tripurar implementationofglucose6phosphatedehydrogenaseg6pdtestingforplasmodiumvivaxcasemanagementamixedmethodstudyfromcambodia
AT adhikarib implementationofglucose6phosphatedehydrogenaseg6pdtestingforplasmodiumvivaxcasemanagementamixedmethodstudyfromcambodia
AT leyb implementationofglucose6phosphatedehydrogenaseg6pdtestingforplasmodiumvivaxcasemanagementamixedmethodstudyfromcambodia
AT pricern implementationofglucose6phosphatedehydrogenaseg6pdtestingforplasmodiumvivaxcasemanagementamixedmethodstudyfromcambodia
AT lekd implementationofglucose6phosphatedehydrogenaseg6pdtestingforplasmodiumvivaxcasemanagementamixedmethodstudyfromcambodia
AT engeln implementationofglucose6phosphatedehydrogenaseg6pdtestingforplasmodiumvivaxcasemanagementamixedmethodstudyfromcambodia
AT thriemerk implementationofglucose6phosphatedehydrogenaseg6pdtestingforplasmodiumvivaxcasemanagementamixedmethodstudyfromcambodia